---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-25-000092"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:33:57.884998+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

## Summary
- Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
- Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.
- Basic/diluted EPS loss $0.13 vs $0.17; adjusted EPS loss $0.02 vs $0.17.
- Completed enrollment of 6,500 patients in the LeAAPS trial.
- Company raised full-year 2025 financial outlook.

## SEC filing metadata
- accession: 0001323885-25-000092
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388525000092/0001323885-25-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388525000092/atrc-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-25-000092
- JSON: https://secwatch.observer/filing/0001323885-25-000092.json
- Plain text: https://secwatch.observer/filing/0001323885-25-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.